(Date:5/16/2008)... Pledge to Save Vital Services for Frail Seniors ...y 16 /PRNewswire-USNewswire/ -- Thousands of,homec...Arnold,Schwarzenegger,s proposed cuts to hours of ...e of California,s most vulnerable workers and the,...d to save these vital,services for seniors and peo...
(Date:5/16/2008)...,What this country needs is more unemployed politi...RNewswire-FirstCall/ -- Although nearly all,voters...tant issues" list,a looming federal budgetary cru...y any of the current presidential candidates is li...Senate Majority Leader Bill Frist., Jousting with...
(Date:5/16/2008)...Four and five year-old Chinese students learn the ...ke of the Sichuan earthquake, NANJING, China, May...ating Sichuan earthquake, even the youngest member...ation and relief efforts. All around the,country, ...ng campaigns.,Led by the school,s principal, Ms. Z...
(Date:5/16/2008)... SAN DIEGO, May 16 /PRNewswire-FirstCall/ -- Cry...y focused on the treatment of cardiac,arrhythmias,...holders of,CryoCor common stock filed a complaint ...County of San Diego, naming as defendants each mem...and Boston Scientific Corporation.,The complaint i...
Breaking Medicine News(10 mins):Health News:Homecare Workers Outraged by Proposed Cuts, Wage Reductions 2Health News:Former Senate Majority Leader, Princeton Economist Joust on Future of Health Care 2Health News:Former Senate Majority Leader, Princeton Economist Joust on Future of Health Care 3Health News:Chinese Preschoolers Participate in Fund Drive to Help the Victims of Sichuan Quake 2Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 2Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 3Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 4(Date:5/16/2008)...ting that TYKERB and trastuzumab together resulted...on-free survival (PFS), -- Combining TYKERB and t...f the HER2 receptor may create a more complete HER...ERB alone despite patients,previous treatment wit... LONDON and PHILADELPHIA, May 16 /PRNewswire-USNew...
(Date:5/16/2008)...er Novel Approach to Blood ...swire-FirstCall/ -- Pharmacopeia (Nasdaq:,PCOP), a...vel small,molecule therapeutics, announced today t...tor Antagonist (DARA), showed statistically signif...y in patients with mild to,moderate hypertension. ...
(Date:5/15/2008)... Patients with breast or,colorectal cancer, two of...er treatment advances with Avastin(R) (bevacizumab...a that is being presented at the 44th,American Soc... Chicago at,the end of May. Around 30,000 medical ...er event for cancer therapy worldwide., The Roche...
(Date:5/15/2008)...table Tolerability Profile, with Low I...AKE, N.J., May 15 /- The investigatio...9) demonstrated activity in a,heavily pretreated p...atic,breast cancer, according to results of a mult...uggests that eribulin mesylate has a manageable,to...
Breaking Medicine Technology:GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 2GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 4GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 5GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 6GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 7Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 2Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 3Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 4Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 6Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 7Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 8New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 2New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 3New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 4New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 5New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 6Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 3ACRIN Study Endorses Virtual Colonoscopy Validation for Colon CAD Software Maker Medicsight plc 440 1ACRIN Study Endorses Virtual Colonoscopy Validation for Colon CAD Software Maker Medicsight plc 440 2ACRIN Study Endorses Virtual Colonoscopy Validation for Colon CAD Software Maker Medicsight plc 440 3ACRIN Study Endorses Virtual Colonoscopy Validation for Colon CAD Software Maker Medicsight plc 440 4Naturally occurring apple compounds reduce risk of pancreatic cancer 668 1Naturally occurring apple compounds reduce risk of pancreatic cancer 668 2Type of ICU Influences Lung Injury Survival 2811 1Type of ICU Influences Lung Injury Survival 2811 2Study Finds Benefits With Drug Coated Stents 2808 1Study Finds Benefits With Drug Coated Stents 2808 2Study Finds Benefits With Drug Coated Stents 2808 3...BUSINESS WIRE)--Jun 20, 2007 - Array BioPharma,Inc...ta on its MEK,inhibitor, ARRY-162, and its p38 inh...the Annual European Congress of Rheumatology,(EULA...ssociation,of Inflammation Societies, (IAIS) 8th W...rk., ARRY-162 / MEK Inhibitor Phase 1 Results , Ar...
...chusetts --- June,20, 2007 --- Millipore Corporati...ing its ReNcell neural stem cell lines. The,resea...at,University College London and ReNeuron Group pl...pore was announced in 2006. ,The data will be pres...ientist for Millipore’s Bioprocess Division,...
Other Medicine Technology:Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory,Drugs 2Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory,Drugs 3Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory,Drugs 4Millipore Corporation Announces New ReNcell Data from Collaboration,with ReNeuron 2Millipore Corporation Announces New ReNcell Data from Collaboration,with ReNeuron 3Millipore Corporation Announces New ReNcell Data from Collaboration,with ReNeuron 4...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
Medicine Products: